20 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
lesions. Beyond providing protection, the immune system regulates key regenerative and homeostatic processes in healthy individuals on an ongoing basis
DEF 14A
w3kotde7 kj4j
29 Apr 22
Definitive proxy
4:24pm
10-K
aljtghc
17 Mar 22
Annual report
4:31pm
8-K
EX-99.1
r9cym1meg
2 Nov 21
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction
4:02pm
8-K
EX-99.1
0orhujk
12 Aug 21
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
10:35am
10-Q
t0nhqe8uisr9rtoos24
14 Jun 21
Quarterly report
4:21pm
8-K
EX-99.1
3bs683m nzfsibvabdnd
14 Jun 21
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business
4:07pm
424B4
0dp3 08plo6
10 May 21
Prospectus supplement with pricing info
4:20pm
S-1/A
2l7oq
3 May 21
IPO registration (amended)
6:07am
S-1
cc5pc5
16 Apr 21
IPO registration
5:03pm
DRS/A
ok5bp5t7a93zd fus
1 Apr 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next